Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Stanley Black & Decker, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.65 (market cap $5.07B), while Stanley Black & Decker, Inc. trades at $103.21 (market cap $15.71B). The key difference: Stanley Black & Decker, Inc. is far larger — about 3.1× ACADIA Pharmaceuticals Inc.'s market cap, and Stanley Black & Decker, Inc. pays a 3.23% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SWK | |
|---|---|---|
Market Cap | $5.07B | $15.71B |
Sector | Health | — |
52-Week High | $29.41 | $104.00 |
52-Week Low | $20.06 | $62.12 |
Enterprise Value | $4.19B | $19.87B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
SWK trades at $102.9, up 0.25% today, with a bullish technical signal from moving averages but overbought RSI levels near 80. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.57 versus $1.21 expected, and raised full-year guidance. Revenue for 2025 was $15.13B, with net income margin improving to 2.65%. Recent news highlights a $1 billion U.S. investment plan and institutional buying, supporting positive momentum.
The outlook is cautiously optimistic, with earnings growth and margin expansion driving potential upside, though the stock trades above the consensus price target of $93.67. Risks include debt levels and economic sensitivity, but institutional accumulation and dividend stability offer support. The current price near resistance at $105 may limit near-term gains despite fundamental improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
